The price of Better Therapeutics Inc (NASDAQ:BTTX) shares last traded on Wall Street rose 23.60% to $0.21.
Based on available information, 2 analysts follow Better Therapeutics Inc (NASDAQ:BTTX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $9.00 and a low of $1.50, we find $5.25. Given the previous closing price of $0.17, this indicates a potential upside of 2988.24 percent. BTTX stock price is now -29.42% away from the 50-day moving average and -72.87% away from the 200-day moving average. The market capitalization of the company currently stands at $9.95M.
Among analysts, 0 rate the stock a hold while 2 rate it a buy. Brokers who have rated the stock have averaged $5.25 as their price target over the next twelve months.
With the price target of $17, Chardan Capital Markets recently initiated with Buy rating for Better Therapeutics Inc (NASDAQ: BTTX).
In other news, PERRY DAVID P, Executive Chairman bought 1,233,045 shares of the company’s stock on Jul 27. The stock was bought for $900,000 at an average price of $0.73. Upon completion of the transaction, the Executive Chairman now directly owns 13,030,393 shares in the company, valued at $2.74 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 27, Director Parker Geoffrey M. bought 685,025 shares of the business’s stock. A total of $500,000 was incurred on buying the stock at an average price of $0.73. This leaves the insider owning 1,028,055 shares of the company worth $0.22 million. A total of 50.83% of the company’s stock is owned by insiders.
A candlestick chart of Better Therapeutics Inc (NASDAQ: BTTX) showed a price of $0.1700 on Friday morning. During the past 12 months, Better Therapeutics Inc has had a low of $0.14 and a high of $1.61. The fifty day moving average price for BTTX is $0.2896 and a two-hundred day moving average price translates $0.7684 for the stock.
The latest earnings results from Better Therapeutics Inc (NASDAQ: BTTX) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.15, beating analysts’ expectations of -$0.19 by 0.04. This compares to -$0.48 EPS in the same period last year. The company reported revenue of $5.34 million for the quarter, compared to $11.0 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -51.43 percent.
Better Therapeutics Inc(BTTX) Company Profile
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company’s lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company’s clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.